In today’s episode, we discuss :MindMed Stock Catalysts for 2021: NASDAQ, Clinical Trial Results and More (MMED / MMEDF).

2020 was a wild year for MindMed, with the company IPOing in March, at just over 20c/ share, all prices in American currency. Then, the MindMed stock price shot up to a high of $4.37 in December, only to fall about 30% and consolidate around $3 a share in the new year.

But what will be the main catalysts for MindMed and its stock going forward in 2021? Put another way, what are the events and dates that shareholders and potential investors should circle on their calendars?

In this episode, we are going to talk about several catalysts to look out for
1. MindMed’s Nasdaq uplisting
– When to expect MindMed to join the Nasdaq?
– Is MindMed’s uplisting a sure thing?
-What will happen to MindMed stock if/when the company gets uplisted?

2. Clinical trials wrapping up, and data being released by MindMed
– Important dates MindMed investors should circle in their calendars
3. MindMed’s quarter end financial reporting
4. MindMed conference calls

Unknown Catalysts for Mindmed:
1. Clinical trials expansions
2. Financial agreements

** Also, on the 20th of January, Kevin O’Leary and Jr Rahn went live discussing MindMed. For those who haven’t seen it, Jr mentioned a few extra catalysts we should be looking forward to which we will discuss in our next episode.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://www.prnewswire.com/news-releases/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round-301178915.html

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Similar Posts

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results)

Learn, Videos

AI CREATING Psychedelics : Is this the FUTURE of the Psychedelic Industry? (+ MDMA Study Results) Today, we’ll be sharing some GAME changing news for the entire psychedelic-medicines industry!

First, we’ll start with some inspiring results from a few MDMA studies and their implications for companies such as Numinus (NUMI), MindMed (MMED / MNMD / MMQ) and Atai Life Sciences. First we’ll cover MAPS’ Phase III MDMA To Treat PTSD Trial Results. Then, we’ll focus on another study’s results, which implies that MDMA could be an effective treatment for alcoholism.

Then, we’ll shift our focus towards an update on Texas, one of the more conservative U.S. states, and its approval of a Psychedelics Research Bill.

Finally, we’ll share some of the oddest and most exciting news from this week: AI might potentially disrupt the psychedelic industry in the next few decades through the creation of psychedelic medicines.

Timestamps:

0:00 – Intro
1:24 – Maps Phase III Trial Testing MDMA to treat PTSD RESULTS & Implications for
Numinus (NUMI), MindMed (MMED / MNMD / MMQ ), Atai, etc.
3:23 – Imperial College of London Study testing MDMA-assisted psychotherapy to treat Alcoholism
7:29 – Texas House Approves a Psychedelic Research Bill
9:34 – Scientists are Using AI to Develop New Psychedelic Drugs

Links to Maps Phase III MDMA trial to treat PTSD : https://www.nytimes.com/2021/05/03/health/mdma-approval.html
https://maps.org/news/media/9122-maps-phase-3-trial-of-mdma-assisted-therapy-for-ptsd-achieves-successful-results-for-patients-with-severe-chronic-ptsd

Links to the Imperial College of London MDMA study to treat alcoholism: https://www.telegraph.co.uk/health-fitness/body/mdma-cured-alcoholism-inside-remarkable-ectsasy-trial-offering/
https://www.telegraph.co.uk/news/2021/02/22/mdma-could-used-treat-alcohol-addiction/

Link to the Texas House Psychedelics Research Bill: https://www.marijuanamoment.net/texas-house-approves-psychedelics-research-bill-as-marijuana-reform-measures-also-advance/

Link to the article “Scientists are Using AI to Develop New Psychedelic Drugs: https://doubleblindmag.com/artificial-intelligence/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #MNMD

Atai is going PUBLIC! Company Rundown and MindMed Comparison

Atai is going PUBLIC! Company Rundown and MindMed Comparison

Learn, Videos

Powered by Restream https://restream.io/

What’s up Psychedelic Investors?!? We have some big news for you. Atai Life Sciences will be going public imminently, directly competing with companies like MindMed (MMED / MMEDF / MMQ) and Numinus (NUMI). This will be a catalyst for the entire sector, and I am excited.

I will be buying some atai when it goes public, how about you?

If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com

Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#AtaiLifeSciences #AtaiIPO #MindMed

Removing Barriers of Accessibility to Psychedelics with Brett Waters

Removing Barriers of Accessibility to Psychedelics with Brett Waters

Listen, Podcasts

Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.